Can CBN help fight skin inflammation?

The search for alternatives to relieve symptoms of inflammatory skin diseases has gained a new chapter. A study shows that cannabinol (CBN), a cannabis compound, reduced signs of inflammation and the severity of lesions similar to atopic dermatitis in mice.

The research also investigated patient samples and skin cells cultured in the laboratory, seeking to understand how the compound acts on inflammatory mechanisms. The findings open new perspectives for the investigation of CBN, but do not yet prove its efficacy as a treatment for eczema in humans. 

What is CBN and what is its relationship with atopic dermatitis?

Cannabinol, known by the acronym CBN, is a phytocannabinoid found in cannabis. Although it is less studied than cannabidiol (CBD) and tetrahydrocannabinol (THC), it has been sparking scientific interest due to its potential biological properties.

Atopic dermatitis is a chronic inflammatory disease that can cause intense itching, dryness, redness, and skin lesions. Its progression involves changes in the skin barrier and immune mechanisms that can intensify symptoms.

In this context, investigating CBN for skin inflammation means understanding whether the compound can interfere with cellular processes associated with the disease, rather than presuming it is already a proven therapy.

How was CBN evaluated for skin inflammation?

According to the study reported by The Marijuana Herald, researchers used a chemically induced atopic dermatitis model in mice. The animals received different doses of CBN, which were assessed through clinical signs, tissue analyses, and molecular markers.

The results indicated a reduction in lesion severity, excessive thickening of the outer skin layer, and mast cell infiltration, cells involved in inflammatory responses.

The researchers also observed changes in signals associated with inflammation, including mediators related to immune response and itching.

In addition, experiments with human keratinocytes cultured in the laboratory helped investigate the mechanisms involved. These cells make up much of the outer layer of the skin and play an important role in maintaining the skin barrier.

Do TRPV1 and CB2 receptors help explain the results?

The research identified elevated levels of TRPV1 and CB2 receptors in skin samples from people with atopic dermatitis and in blood immune cells. The expression of these receptors was also associated with disease severity.

In laboratory experiments, reducing the expression of TRPV1 or CB2 eliminated the additional effect of CBN on the activity of proteins involved in inflammatory signaling, called JAK2 and STAT6.

These findings suggest that the receptors may participate in the mechanisms through which cannabinol modulates inflammation. However, identifying a potential biological pathway does not mean that the compound will produce the same clinical effect in patients.

LEARN MORE: Cannabinoids in the treatment of atopic dermatitis: therapeutic potential and perspectives

Can medical cannabis be used to treat eczema?

Despite the promising results, it is still too early to state that CBN is effective or safe for treating atopic dermatitis in humans. Experiments with animals and cells are important stages of research, but they do not replace clinical trials that evaluate efficacy, safety, dosage, and potential adverse effects.

It is also necessary to investigate which formulations would be appropriate, how the compound could be administered, and whether the observed benefits would be replicated across different patient profiles.

People with eczema should maintain dermatological follow-up and not replace prescribed treatments with cannabis-based products without professional guidance.

Science advances precisely like this: investigating possibilities, testing hypotheses, and recognizing the limits of each discovery. For those living with a chronic skin condition, each new line of research represents an opportunity to expand knowledge, without confusing hope with proof.